Wave Life Sciences Ltd. (WVE) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Wave Life Sciences Ltd. (WVE:NASDAQ), powered by AI.

Current Price
$5.74
P/E Ratio
-4.7
Market Cap
968M
Sector
Healthcare
What is the Wave Life Sciences Ltd. stock price forecast?

Wave Life Sciences Ltd. is currently trading at $5.74. View real-time AI analysis on Alpha Lenz.

What is Wave Life Sciences Ltd. insider trading activity?

View the latest insider trading data for Wave Life Sciences Ltd. on Alpha Lenz.

What is Wave Life Sciences Ltd.'s P/E ratio?

Wave Life Sciences Ltd.'s P/E ratio is -4.7.

Wave Life Sciences Ltd.

NASDAQ · WVE
$5.74-0.26(-4.33%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Wave Life Sciences Ltd.'s future dividend policy...
Alpha Chat Insight

Wave Life Sciences Ltd. trades at a P/E of -4.7 (undervalued) with modest ROE of -56.2%. 3Y revenue CAGR of 127.1% highlights clear growth momentum.

Ask for details

Company Overview

Wave Life Sciences Ltd. is a biotechnology company engaged in the research and development of stereopure nucleic acid therapies. The primary focus of Wave Life Sciences is to leverage its unique platform to design and optimize therapies that modulate RNA to address genetic diseases. This involves developing treatments with high specificity and efficacy, potentially offering advantages over traditional nucleic acid therapies. The company targets a range of serious diseases, including those related to the central nervous system, with its innovative therapies. Wave Life Sciences plays a significant role in the biopharmaceutical industry by expanding the potential of gene medicine. Its work has implications for sectors such as healthcare and pharmaceuticals, especially in developing new treatment modalities for unmet medical needs. The company's research and development efforts are geared towards delivering transformational outcomes for patients, positioning it as a pioneer in the evolving field of genetic medicine. Wave Life Sciences Ltd. claims a critical space within the market for its advancements in precision medicine and continues to collaborate with various stakeholders to push the boundaries of therapeutic development.

CEODr. Paul B. Bolno M.B.A., M.D.
SectorHealthcare
IndustryBiotechnology
Employees287

Company Statistics

FY 2025

Profile

$968.05MMarket Cap
$42.73MRevenue
0.00Shares Out
287Employees

Margins

N/AGross
-507.90%EBITDA
-504.09%Operating
-478.33%Pre-Tax
-478.33%Net

Valuation

-4.74P/E
1.87P/B
22.66EV/Sales
-1.77EV/EBITDA
-5.14P/FCF

Growth (CAGR)

127.08%Rev 3Yr
16.31%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-41.26%ROA
-56.16%ROE
-43.48%ROIC

Financial Health

$602.07MCash & Cash Equivalents
$-481.93MNet Debt
23.18%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Wave Life Sciences Ltd. (ticker: WVE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 287 employees. Market cap is $968M.

The current price is $5.74 with a P/E ratio of -4.74x and P/B of 1.87x.

ROE is -56.16% and operating margin is -504.09%. Annual revenue is $43M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Wave Life Sciences Ltd. (WVE) Stock Forecast 2026 $5.74 — Price, Financials & Analyst Targets | Alpha Lenz